Frequency of epidermal growth factor receptor mutations in Bangladeshi patients with adenocarcinoma of the lung

Rahman, Shakibur; Kondo, Nobuyuki; Yoneda, Kazue; Takuwa, Teruhisa; Hashimoto, Masaki; Orui, Hayato; Okumura, Yoshitomo; Tanaka, Fumihiro; Kumamoto, Kenzo; Mostafa, Mohammad Golam; Chowdhury, Golam Mohiuddin; Haque, A. K.; Hasegawa, Seiki

doi:10.1007/s10147-012-0515-4

Cited by 19 publications

(13 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other studies from India have also shown similar female predominance in EGFR mutation [1, 17]. A study from Bangladesh reported an exception to this pattern where Rahman et al reported higher EGFR mutation rate in men than women (25.5% men, 14.3% women) [18].…”

Section: Discussionmentioning

confidence: 78%

Epidermal Growth Factor Receptor Mutation Frequency in Squamous Cell Carcinoma and Its Diagnostic Performance in Cytological Samples: A Molecular and Immunohistochemical Study

et al. 2019

View full text Add to dashboard Cite

Background Epidermal growth factor receptor (EGFR) mutation is the most frequent mutation tested in lung cancer for targeted therapy in the era of personalized medicine. Knowledge about EGFR mutation is constantly expanding regarding its frequency, clinicopathological association, advancements in testing methodology and sample requirement. We investigated EGFR mutation frequency in non-small cell lung cancer (NSCLC) in North Indian patients and evaluated its diagnostic performance in cytological samples. Methods Molecular EGFR testing was done in 250 cases of NSCLC by both real-time polymerase chain reaction (PCR) (Therascreen) and mutation-specific EGFR immunohistochemistry (IHC). Thirty cases had both cytology samples and biopsy including 20 pleural effusions and 10 fine-needle aspirates. EGFR mutation concordance between pleural effusion and biopsy was studied. Results EGFR mutation was overall 31.6% in NSCLC with 36.5% in adenocarcinoma and 15% in squamous cell carcinoma. L858R mutation accounted for 50.7% and DEL19 for 39.3% of total EGFR mutations. Complex mutations were seen in 2% of cases. Sensitivity of mutation-specific EGFR IHC was 48.3% and specificity was 92.3%. L858R showed higher sensitivity (55% vs. 33.3%) but similar specificity (93.2% vs. 91.3%) compared to DEL19. EGFR mutation was successful in 95% of pleural effusion and showed 83.3% concordance with tissue biopsy. Conclusions EGFR mutation frequency in North Indian patients was comparable to that of Asia-Pacific region and showed a similar pattern of histological distribution. EGFR mutation in squamous cell carcinomas is increasingly recognized which was 15% in our study. Mutation-specific EGFR IHC shows variable but generally low sensitivity and considering its significant pre- and post-analytical variables, it should be highly discouraged in patient management. Cytological samples may not only serve as suitable alternative but may be complementary to tissue biopsies.

show abstract

Section: Discussionmentioning

confidence: 78%

Epidermal Growth Factor Receptor Mutation Frequency in Squamous Cell Carcinoma and Its Diagnostic Performance in Cytological Samples: A Molecular and Immunohistochemical Study

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Tanaka et al 4 East Asian (Japan) 104/242 (43%) Choi et al 5 East Asian (Korea) 203/521 (39%) Rahman et al 11 South Asian (Bangladesh) 14/61 (23%) Castro et al 6 White 29/216 (13%) Smits et al 10 White 66/620 (11%) This study North African 29/137 (21%) EGFR, epidermal growth factor receptor. Huang et al 7 Asian 35 48 Shigematsu et al 8 American 44 41 Castro et al 6 White 39 33 De Mello et al 12 White 50 45 This study North African 69 21…”

Section: Race Egfr Mutation (%)mentioning

confidence: 77%

“…Some previous studies have demonstrated a genetic divergence of EGFR mutation rates according to ethnicity. [4][5][6]10,11 Indeed, the EGFR mutation rate in East-Asian patients (39%-43%) is much higher than that of the white population (11%-13%) whereas some races, such South-Asian, have an intermediate rate (23%). EGFR mutation frequency in Moroccan patients, as reported in this study, is higher than that found in whites but lower than in Asians.…”

Section: Discussionmentioning

confidence: 99%

Frequency and Type of Epidermal Growth Factor Receptor Mutations in Moroccan Patients with Lung Adenocarcinoma

Errihani¹,

Inrhaoun²,

Boukir³

et al. 2013

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

“…The frequency of EGFR mutations is much higher in individuals of Asian origin (45-50%) than in individuals from Western Europe (10-15%) or North America (15-20%). It is noteworthy that high variability has been reported in the prevalence of EGFR mutations within the Asian-Pacific population, with a higher frequency in Vietnam (64.2%), Thailand (53.8%) and China (50.2%) than in India (22.2%) or Bangladesh (23%) [70,71]. This variability has also been observed in South America, with a higher proportion of EGFR mutations among the Amerindian subpopulation (principally Peru, 67%, but also Mexico, 31.2%, and Colombia, 24.8%) compared to Caucasian populations (Argentina, 19.3%) [72].…”

Section: Epidemiologymentioning

confidence: 99%

Molecular biomarkers for lung adenocarcinoma

et al. 2017

View full text Add to dashboard Cite

The identification of oncogenic driver alterations that underlie sensitivity to small inhibitors has led to growing interest in identifying additional targetable oncogenes in nonsmall cell lung cancer. Although the therapeutic impact of the discovery of these alterations has now been widely demonstrated, the epidemiological data associated with each of these biomarkers remain insufficiently studied. In this review, we discuss the techniques used to discover each of these candidate oncogenes, their prevalence in nonsmall cell lung cancer, and briefly outline the epidemiological features of the major oncogenes and ways in which their identification can determine therapeutic strategies.

show abstract

Frequency of epidermal growth factor receptor mutations in Bangladeshi patients with adenocarcinoma of the lung

Abstract: The present study revealed that the EGFR mutation rate in Bangladeshi patients with adenocarcinoma of the lung was higher than in African-American, Arabian, and white Caucasian patients, and was lower than in East Asia.

Cited by 19 publications

References 17 publications

Epidermal Growth Factor Receptor Mutation Frequency in Squamous Cell Carcinoma and Its Diagnostic Performance in Cytological Samples: A Molecular and Immunohistochemical Study

Epidermal Growth Factor Receptor Mutation Frequency in Squamous Cell Carcinoma and Its Diagnostic Performance in Cytological Samples: A Molecular and Immunohistochemical Study

Frequency and Type of Epidermal Growth Factor Receptor Mutations in Moroccan Patients with Lung Adenocarcinoma

Molecular biomarkers for lung adenocarcinoma

Contact Info

Product

Resources

About